In silico receptor binding and ex vivo nasal epithelial membrane permeation studies of selected phytocannabinoids.

Area of Science:

• Neurology
• Pharmacology
• Natural Products

Background:

• Migraine headaches are debilitating neurological disorders.
• Cannabinoid receptors are potential therapeutic targets for migraine.
• Cannabis sativa is used for self-medication of headaches, but scientific data on receptor interactions and intranasal delivery is limited.

Purpose of the Study:

• Investigate the potential of Cannabis sativa compounds for migraine treatment.
• Evaluate the feasibility of intranasal delivery for systemic and nose-to-brain administration of these compounds.

Main Methods:

• In silico docking of Cannabis sativa phytochemicals into the CB2 receptor active site.
• Ex vivo permeation studies of selected cannabinoid compounds across sheep nasal epithelial tissue.

Main Results:

• Four cannabinoid compounds (cannabicyclol, cannabidiolic acid, cannabicitran, cannabielsoin) demonstrated affinity for the CB2 receptor.
• Ex vivo studies indicated that some cannabinoids can permeate nasal epithelium for systemic and potential nose-to-brain delivery.

Conclusions:

• Identified compounds show promise for migraine treatment via CB2 receptor affinity.
• Intranasal administration offers a viable route for nose-to-brain delivery of these cannabinoids.